Bessemer Group Inc. Has $4.45 Million Stock Holdings in ANI Pharmaceuticals, Inc. $ANIP

Bessemer Group Inc. lifted its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 52.0% in the first quarter, Holdings Channel.com reports. The fund owned 57,909 shares of the specialty pharmaceutical company’s stock after acquiring an additional 19,800 shares during the quarter. Bessemer Group Inc.’s holdings in ANI Pharmaceuticals were worth $4,454,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Advisors Asset Management Inc. acquired a new stake in ANI Pharmaceuticals during the 1st quarter valued at approximately $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of ANI Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock worth $736,000 after purchasing an additional 470 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of ANI Pharmaceuticals by 0.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $2,706,000. Finally, Norges Bank acquired a new stake in shares of ANI Pharmaceuticals during the second quarter worth $625,000. 76.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ANIP shares. Canaccord Genuity Group started coverage on shares of ANI Pharmaceuticals in a research note on Thursday. They set a “hold” rating and a $91.00 target price for the company. Guggenheim reaffirmed a “buy” rating and set a $124.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, July 10th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Finally, Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $105.00.

ANI Pharmaceuticals Trading Down 1.9%

NASDAQ ANIP opened at $77.72 on Tuesday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. ANI Pharmaceuticals, Inc. has a 52 week low of $62.60 and a 52 week high of $99.50. The business has a 50 day moving average price of $81.36 and a 200-day moving average price of $79.49. The company has a market cap of $1.77 billion, a price-to-earnings ratio of 19.68 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. ANI Pharmaceuticals had a return on equity of 27.51% and a net margin of 9.98%.The company had revenue of $237.46 million for the quarter, compared to analysts’ expectations of $207.63 million. During the same period last year, the business earned $1.70 EPS. ANI Pharmaceuticals’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 earnings per share for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the transaction, the director directly owned 38,432 shares of the company’s stock, valued at approximately $3,098,772.16. This trade represents a 20.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Ori Gutwerg sold 2,772 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $79.50, for a total transaction of $220,374.00. Following the transaction, the senior vice president owned 78,696 shares of the company’s stock, valued at $6,256,332. This represents a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 85,179 shares of company stock valued at $6,722,596. 8.10% of the stock is currently owned by insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.